GBP20.26
1.35% yesterday
London, Jun 27, 05:35 pm CET
ISIN
GB00B0LCW083
Symbol
HIK
Sector
Industry

Hikma Pharmaceuticals Stock price

GBP20.26
-0.86 4.07% 1M
+0.78 4.01% 6M
+0.67 3.43% YTD
+2.04 11.21% 1Y
+4.85 31.46% 3Y
-0.02 0.10% 5Y
+4.68 30.02% 10Y
+18.14 856.70% 20Y
London, Closing price Fri, Jun 27 2025
+0.27 1.35%
ISIN
GB00B0LCW083
Symbol
HIK
Sector
Industry

Key metrics

Basic
Market capitalization
GBP4.4b
Enterprise Value
GBP5.2b
Net debt
GBP796.6m
Cash
GBP155.2m
Shares outstanding
221.9m
Valuation (TTM | estimate)
P/E
17.32 | 11.77
P/S
1.92 | 1.78
EV/Sales
2.26 | 2.10
EV/FCF
21.70
P/B
2.67
Dividends
DPS
GBP0.61
Yield 1Y | 5Y
3.01% | 2.35%
Growth 1Y | 5Y
37.55% | 12.40%
Payout 1Y | 3Y
52.13% | 61.39%
Increased
19 Years
Financials (TTM | estimate)
Revenue
GBP2.3b | GBP2.5b
EBITDA
GBP525.5m | GBP656.2m
EBIT
GBP458.4m
Net Income
GBP261.6m | GBP381.9m
Free Cash Flow
GBP239.8m
Growth (TTM | estimate)
Revenue
9.77% | 7.89%
EBITDA
1.55% | 24.87%
EBIT
1.13%
Net Income
88.95% | 45.96%
Free Cash Flow
-18.56%
Margin (TTM | estimate)
Gross
45.88%
EBITDA
22.85% | 26.44%
EBIT
19.93%
Net
11.38% | 15.39%
Free Cash Flow
10.42%
Financial Health
Equity Ratio
45.00%
Return on Equity
15.54%
ROCE
19.94%
ROIC
12.96%
Debt/Equity
0.57
More
EPS
GBP1.17
FCF per Share
GBP1.08
Short interest
119.00%
Employees
9.50k
Rev per Employee
GBP240.00k
Show more

Is Hikma Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Hikma Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Hikma Pharmaceuticals forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Hikma Pharmaceuticals forecast:

Buy
84%
Hold
16%

Financial data from Hikma Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,300 2,300
10% 10%
100%
- Direct Costs 1,245 1,245
16% 16%
54%
1,055 1,055
3% 3%
46%
- Selling and Administrative Expenses 414 414
4% 4%
18%
- Research and Development Expense 103 103
5% 5%
4%
525 525
2% 2%
23%
- Depreciation and Amortization 67 67
5% 5%
3%
EBIT (Operating Income) EBIT 458 458
1% 1%
20%
Net Profit 262 262
89% 89%
11%

In millions GBP.

Don't miss a Thing! We will send you all news about Hikma Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Riad Mishlawi
Employees 9,500
Founded 1978
Website www.hikma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today